404. Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am J Clin Oncol. ‒ 1982. ‒ T. 5, № 6. ‒ C. 649-55.
405. Simmons C., McMillan D. C., Tuck S., Graham C., McKeown A., Bennett M., O'Neill C., Wilcock A., Usborne C., Fearon K. C., Fallon M., Laird B. J., Group I. S. "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer // Oncologist. ‒ 2019.10.1634/theoncologist.2018-0474.
406. Tse A., Verkhivker G. M. Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways // PLoS One. ‒ 2016. ‒ T. 11, № 11. ‒ C. e0166583.
407. Zhang C., Spevak W., Zhang Y., Burton E. A., Ma Y., Habets G., Zhang J., Lin J., Ewing T., Matusow B., Tsang G., Marimuthu A., Cho H., Wu G., Wang W., Fong D., Nguyen H., Shi S., Womack P., Nespi M., Shellooe R., Carias H., Powell B., Light E., Sanftner L., Walters J., Tsai J., West B. L., Visor G., Rezaei H., Lin P. S., Nolop K., Ibrahim P. N., Hirth P., Bollag G. RAF inhibitors that evade paradoxical MAPK pathway activation // Nature. ‒ 2015. ‒ T. 526, № 7574. ‒ C. 583-586.
408. Larkin J., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J., Cowey C. L., Lao C. D., Schadendorf D., Ferrucci P. F., Smylie M., Dummer R., Hill A., Haanen J., Maio M., McArthur G., Walker D., Rollin L., Horak C., Hodi F. S., Wolchok J. D. Overall Survival Results From a Phase III Trial of Nivolumab Combined With Ipilimumab in Treatment-naïve Patients With Advanced Melanoma (CheckMate 067) // AACR Annual Meeting ‒ Walter E. Washington Convention Center, Washington, D.C., USA, 2017. ‒.
409. Long G. V., Atkinson V., Lo S., Sandhu S., Guminski A. D., Brown M. P., Wilmott J. S., Edwards J., Gonzalez M., Scolyer R. A., Menzies A. M., McArthur G. A. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study // Lancet Oncol. ‒ 2018. ‒ T. 19, № 5. ‒ C. 672-681.
410. Postow M. A., Chesney J., Pavlick A. C., Robert C., Grossmann K., McDermott D., Linette G. P., Meyer N., Giguere J. K., Agarwala S. S., Shaheen M., Ernstoff M. S., Minor D., Salama A. K., Taylor M., Ott P. A., Rollin L. M., Horak C., Gagnier P., Wolchok J. D., Hodi F. S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma // N Engl J Med. ‒ 2015. ‒ T. 372, № 21. ‒ C. 2006-17.
411. Tawbi H. A., Forsyth P. A., Algazi A., Hamid O., Hodi F. S., Moschos S. J., Khushalani N. I., Lewis K., Lao C. D., Postow M. A., Atkins M. B., Ernstoff M. S., Reardon D. A., Puzanov I., Kudchadkar R. R., Thomas R. P., Tarhini A., Pavlick A. C., Jiang J., Avila A., Demelo S., Margolin K. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain // N Engl J Med. ‒ 2018. ‒ T. 379, № 8. ‒ C. 722-730.
412. Ascierto P. A., Mandala M., Ferrucci P. F., Guidoboni M., Rutkowski P., Ferraresi V., Arance A., Guida M., Maiello E., Gogas H., Richtig E., Fierro M. T., Lebbe C., Helgadottir H., Queirolo P., Spagnolo F., Tucci M., Del Vecchio M., Gonzales Cao M., Minisini A. M., De Placido S., Sanmamed M. F., Mallardo D., Curvietto M., Melero I., Palmieri G., Grimaldi A. M., Giannarelli D., Dummer R., Chiarion Sileni V. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial // J Clin Oncol. ‒ 2023. ‒ T. 41, № 2. ‒ C. 212-221.
413. Atkins M. B., Lee S. J., Chmielowski B., Ribas A., Tarhini A. A., Truong T.-G., Davar D., O'Rourke M. A., Curti B. D., Brell J. M., Kendra K. L., Ikeguchi A., Wolchok J. D., Kirkwood J. M. DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134 // Journal of Clinical Oncology. ‒ 2021. ‒ T. 39, № 36_suppl. ‒ C. 356154-356154.
414. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J. J., Cowey C. L., Lao C. D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., Ferrucci P. F., Hill A., Wagstaff J., Carlino M. S., Haanen J. B., Maio M., Marquez-Rodas I., McArthur G. A., Ascierto P. A., Long G. V., Callahan M. K., Postow M. A., Grossmann K., Sznol M., Dreno B., Bastholt L., Yang A., Rollin L. M., Horak C., Hodi F. S., Wolchok J. D. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma // N Engl J Med. ‒ 2015. ‒ T. 373, № 1. ‒ C. 23-34.
415. Weber J. S., D'Angelo S. P., Minor D., Hodi F. S., Gutzmer R., Neyns B., Hoeller C., Khushalani N. I., Miller W. H., Jr., Lao C. D., Linette G. P., Thomas L., Lorigan P., Grossmann K. F., Hassel J. C., Maio M., Sznol M., Ascierto P. A., Mohr P., Chmielowski B., Bryce A., Svane I. M., Grob J. J., Krackhardt A. M., Horak C., Lambert A., Yang A. S., Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial // Lancet Oncol. ‒ 2015. ‒ T. 16, № 4. ‒ C. 375-84.
416. Robert C., Schachter J., Long G. V., Arance A., Grob J. J., Mortier L., Daud A., Carlino M. S., McNeil C., Lotem M., Larkin J., Lorigan P., Neyns B., Blank C. U., Hamid O., Mateus C., Shapira-Frommer R., Kosh M., Zhou H., Ibrahim N., Ebbinghaus S., Ribas A., investigators K.-. Pembrolizumab versus Ipilimumab in Advanced Melanoma // N Engl J Med. ‒ 2015. ‒ T. 372, № 26. ‒ C. 2521-32.
417. Robert C., Ribas A., Wolchok J. D., Hodi F. S., Hamid O., Kefford R., Weber J. S., Joshua A. M., Hwu W. J., Gangadhar T. C., Patnaik A., Dronca R., Zarour H., Joseph R. W., Boasberg P., Chmielowski B., Mateus C., Postow M. A., Gergich K., Elassaiss-Schaap J., Li X. N., Iannone R., Ebbinghaus S. W., Kang S. P., Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial // Lancet. ‒ 2014. ‒ T. 384, № 9948. ‒ C. 1109-17.